Literature DB >> 8985031

Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer: evaluation by computed tomography and magnetic resonance imaging.

T Mizowaki1, Y Nishimura, Y Shimada, Y Nakano, M Imamura, J Konishi, M Hiraoka.   

Abstract

PURPOSE: To determine the optimal size criterion for detection of lymph node metastases from esophageal cancer for radiotherapy by computed tomography (CT) and magnetic resonance (MR) imaging. METHODS AMD MATERIALS: In 58 patients with esophageal cancer treated with subtotal esophagectomy and radical lymph node dissection the preoperative MR (n = 58) images and CT scans (n = 41) were reviewed. The relationship of the CT and MR findings for the neck and mediastinum to the surgical and histopathological results was examined. Five size criteria on malignant lymph nodes were used to construct receiver operating characteristic (ROC) curves for CT and MR, and their detectabilities were evaluated.
RESULTS: The specificities of both modalities at the cutoff of 3 mm short-axis diameter were lower than those at the cutoff of 5 mm or more. In contrast, the sensitivities apparently decreased at the cutoff of 10 mm or more. The analysis of the ROC curves showed that the optimal size criterion for malignant lymph nodes was 5 mm for both CT and MR. When the criterion of 5 mm was used, the sensitivity, specificity, and accuracy for CT was 68, 92, and 87%, respectively, and the respective values for MR were 70, 93, and 89%. Although there was no significant difference between the two ROC curves, MR was useful in distinguishing lymph nodes from vascular structures because of the flow void.
CONCLUSIONS: There was no significant difference between CT and MR in the detection of malignant lymph nodes from esophageal cancer. The optimal size criterion for both CT and MR in the detection of cervical and mediastinal lymph node metastases is 5 mm for short-axis diameter. These results suggest that all regional lymph nodes of 5 mm or more on CT or MR should be regarded as part of the gross tumor volume in the treatment planning of radiotherapy for esophageal cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8985031     DOI: 10.1016/s0360-3016(96)00425-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Accuracy of MRI for the diagnosis of metastatic cervical lymphadenopathy in patients with thyroid cancer.

Authors:  Qinghua Chen; Prashant Raghavan; Sugoto Mukherjee; Mark J Jameson; James Patrie; Wenjun Xin; Junfang Xian; Zhenchang Wang; Paul A Levine; Max Wintermark
Journal:  Radiol Med       Date:  2015-03-01       Impact factor: 3.469

2.  Lymphatic tumor emboli detected by D2-40 immunostaining can more accurately predict lymph-node metastasis.

Authors:  Hiromitsu Moriya; Makoto Ohbu; Nobuyuki Kobayashi; Satoshi Tanabe; Natsuya Katada; Nobue Futawatari; Shinichi Sakuramoto; Shiro Kikuchi; Isao Okayasu; Masahiko Watanabe
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

3.  Clinical Significance of the Pre-therapeutic Nodal Size in Patients Undergoing Neo-Adjuvant Treatment Followed by Esophagectomy for Esophageal Squamous Cell Carcinoma.

Authors:  Shinji Mine; Masayuki Watanabe; Yu Imamura; Akihiko Okamura; Takanori Kurogochi; Takeshi Sano
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

Review 4.  Imaging strategies in the management of oesophageal cancer: what's the role of MRI?

Authors:  Peter S N van Rossum; Richard van Hillegersberg; Frederiek M Lever; Irene M Lips; Astrid L H M W van Lier; Gert J Meijer; Maarten S van Leeuwen; Marco van Vulpen; Jelle P Ruurda
Journal:  Eur Radiol       Date:  2013-02-13       Impact factor: 5.315

5.  Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy.

Authors:  Katsuyuki Sakanaka; Yuichi Ishida; Satoshi Itasaka; Yasumasa Ezoe; Ikuo Aoyama; Shinichi Miyamoto; Takahiro Horimatsu; Manabu Muto; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2016-03-02       Impact factor: 3.402

6.  A nomogram prediction model for recurrent laryngeal nerve lymph node metastasis in thoracic oesophageal squamous cell carcinoma.

Authors:  Yu Liu; Zhi-Qiang Zou; Juan Xiao; Mei Zhang; Lei Yuan; Xiao-Gang Zhao
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

7.  Prognostic significance of preoperative lymph node assessment for patients with stage pN0 esophageal squamous cell carcinoma after esophagectomy.

Authors:  Yan Shi; Jinming Xu; Ying Wang; Jie Tang; Chong Zhang; Wang Lv; Jian Hu
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

8.  Mapping of Cervical and Upper Mediastinal Lymph Node Recurrence for Guiding Clinical Target Delineation of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma.

Authors:  Yichun Wang; Dongmei Ye; Mei Kang; Liyang Zhu; Mingwei Yang; Jun Jiang; Wanli Xia; Ningning Kang; Xiangcun Chen; Jie Wang; Fan Wang
Journal:  Front Oncol       Date:  2021-04-26       Impact factor: 6.244

9.  Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).

Authors:  M van Heijl; J J B van Lanschot; L B Koppert; M I van Berge Henegouwen; K Muller; E W Steyerberg; H van Dekken; B P L Wijnhoven; H W Tilanus; D J Richel; O R C Busch; J F Bartelsman; C C E Koning; G J Offerhaus; A van der Gaast
Journal:  BMC Surg       Date:  2008-11-26       Impact factor: 2.102

10.  Development of a prediction model for the risk of recurrent laryngeal nerve lymph node metastasis in thoracolaparoscopic esophagectomy with cervical anastomosis.

Authors:  Guoqing Zhang; Yuanqi Li; Qian Wang; Huiwen Zheng; Lulu Yuan; Zhen Gao; Jindong Li; Xiangnan Li; Song Zhao
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.